Top
image credit: Michael J. Ermarth/Flickr

FDA approves new drug that could aid MS diagnoses for clinical trials

January 27, 2020

Category:

A new drug that could make it easier for doctors to diagnose multiple sclerosis (MS) in its earlier stages has been approved for its first human trials by the U.S. Food and Drug Administration (FDA).

Created by Case Western Reserve researchers, the drug known as Myeliviz will be tested in clinical trials involving healthy volunteers at Cleveland Clinic Mellen Center for Multiple Sclerosis.

An autoimmune disease affecting 2.3 million people worldwide, according to the National Multiple Sclerosis Society (NMSS), MS can be a particularly difficult disease to diagnose. That’s especially true in its early stages, due to unpredictable combinations of symptoms and their severity, and because of limitations in other available imaging methods.

Read More on The Medical News